Cabaletta Bio, INC. (CABA) — SEC Filings

Overview

Cabaletta Bio, INC. (CABA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: Cabaletta Bio, Inc. filed an 8-K on April 20, 2026, reporting other events and financial statements. The filing includes various exhibits, such as the main 8-K document and supplemental information in EX-99.1, along with numerous graphic files.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 45 neutral. The dominant filing sentiment for Cabaletta Bio, INC. is neutral.

Filing Type Overview

Cabaletta Bio, INC. (CABA) has filed 21 8-K, 6 10-Q, 2 DEF 14A, 16 SC 13G/A, 4 SC 13G, 1 10-K with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Cabaletta Bio Files 8-K with Exhibits — 8-K · Apr 20, 2026 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on April 20, 2026, reporting other events and financial statements. The filing includes various exhibits, such as the main 8-K
• Cabaletta's Burn Rate Soars Amid R&D Push, Raising Going Concern Doubts — 10-Q · Nov 10, 2025 Risk: high
  Cabaletta Bio, Inc. (CABA) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $125.9 million, up from $83.3 mill
• Cabaletta Bio Files 8-K Report — 8-K · Oct 29, 2025 Risk: low
  On October 29, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2929 Arch Street, Su
• Cabaletta Bio Files 8-K Report — 8-K · Oct 27, 2025 Risk: low
  On October 27, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Reg
• Cabaletta Bio, Inc. Files 8-K — 8-K · Oct 9, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on October 9, 2025, to report current information. The filing confirms the company's principal executive offices are located at
• 8-K Filing — 8-K · Sep 3, 2025
• Cabaletta's Q2 Loss Narrows Marginally Amid R&D Cost Cuts — 10-Q · Aug 7, 2025 Risk: high
  Cabaletta Bio, Inc. reported a net loss of $28.9 million for the quarter ended June 30, 2025, a slight increase from the $28.0 million net loss in the same peri
• Cabaletta Bio, Inc. Files 8-K: Material Definitive Agreement — 8-K · Jun 12, 2025 Risk: medium
  On June 11, 2025, Cabaletta Bio, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements and exhibits.
• Cabaletta Bio Terminates Material Definitive Agreement — 8-K · Jun 11, 2025 Risk: medium
  Cabaletta Bio, Inc. announced on June 11, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware with its principal exe
• Cabaletta Bio Files 8-K on Corporate Actions — 8-K · Jun 10, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on June 10, 2025, reporting on events that occurred on June 9, 2025. The filing primarily concerns amendments to its articles o
• Cabaletta Bio Announces Board and Executive Changes — 8-K · May 19, 2025 Risk: medium
  On May 15, 2025, Cabaletta Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the electi
• Cabaletta Bio Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Cabaletta Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations.
• Cabaletta Bio: Executive Compensation Details Revealed — DEF 14A · May 13, 2025 Risk: medium
  Cabaletta Bio, Inc. filed a DEF 14A on May 13, 2025, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes informat
• Cabaletta Bio Files 8-K for Operations and Financials — 8-K · Mar 31, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition, as well as presenting financial statements a
• Cabaletta Bio Files 8-K Report — 8-K · Feb 18, 2025 Risk: low
  On February 18, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• Cabaletta Bio Files 8-K on Financials and Operations — 8-K · Jan 13, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information relat
• SC 13G/A Filing — SC 13G/A · Dec 6, 2024
• SC 13G/A Filing — SC 13G/A · Dec 5, 2024
• SC 13G/A Filing — SC 13G/A · Dec 5, 2024
• Cabaletta Bio Files 8-K — 8-K · Nov 18, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on November 18, 2024, to report on other events and financial statements. The filing does not contain specific details about ne
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Cabaletta Bio Q3 2024 Update: Financing & Operations — 10-Q · Nov 14, 2024 Risk: medium
  Cabaletta Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations, including
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• Sanofi Acquires Cabaletta Bio for $93M — 8-K · Oct 7, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on October 7, 2024, that it has entered into a definitive agreement to be acquired by European pharmaceutical company Sanofi for a
• Cabaletta Bio Enters Material Definitive Agreement — 8-K · Sep 30, 2024 Risk: medium
  On September 30, 2024, Cabaletta Bio, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its t
• SC 13G Filing — SC 13G · Aug 22, 2024
• Sanofi to Acquire Cabaletta Bio for $950 Million — 8-K · Aug 8, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for $9.50 per share in cash, represent
• Cabaletta Bio Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Cabaletta Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operatio
• Cabaletta Bio Acquires Syncona Gene Therapy Portfolio — 8-K · Jun 14, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on June 14, 2024, that it has entered into a definitive agreement to acquire Syncona Limited's portfolio of gene therapy assets. T
• SC 13G Filing — SC 13G · Jun 10, 2024
• SC 13G Filing — SC 13G · Jun 6, 2024
• Cabaletta Bio Reports Shareholder Vote Matters — 8-K · Jun 4, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on June 4, 2024, to report on matters submitted to a vote of its security holders. The filing details the submission of specifi
• Cabaletta Bio Files 8-K on Operations and Financials — 8-K · May 15, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclos
• Cabaletta Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  Cabaletta Bio, Inc. (CABA) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Cabaletta Bio, Inc. filed a 10-Q report for the period ending March 31,
• Cabaletta Bio, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 23, 2024 Risk: low
  Cabaletta Bio, Inc. (CABA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Cabaletta Bio, Inc. will hold its 2024 Annual Meeting of Stockholde
• Cabaletta Bio, Inc. Files 8-K on Financials — 8-K · Mar 21, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition, and including financial statements and exhib
• Cabaletta Bio, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: medium
  Cabaletta Bio, Inc. (CABA) filed a Annual Report (10-K) with the SEC on March 21, 2024. Cabaletta Bio, Inc. filed its 10-K report for the fiscal year ending Dec
• Cabaletta Bio Files 8-K — 8-K · Mar 20, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Deerfield Mgmt Cuts Cabaletta Bio Stake to 1 Shared Vote — SC 13G/A · Feb 12, 2024 Risk: medium
  Deerfield Mgmt, L.P., a Delaware-organized entity, has filed an amended SC 13G/A for Cabaletta Bio, Inc. (NASDAQ: CABA) as of December 31, 2023. This filing ind

Related Companies

CRTX · SNY · CABO

Frequently Asked Questions